CLB - Core Laboratories NV Stock Price, Fair Value and News

16.54USD-0.45 (-2.65%)Market Closed

Market Summary

USD16.54-0.45

Market Closed

-2.65%

CLB Stock Price

View Fullscreen

CLB RSI Chart

CLB Valuation

Market Cap

681.3M

Price/Earnings (Trailing)

28.73

Price/Sales (Trailing)

1.36

EV/EBITDA

Price/Free Cashflow

106.96

CLB Price/Sales (Trailing)

CLB Profitability

Free Cashflow Yield

0.93%

CLB Fundamentals

CLB Revenue

CLB Earnings

Breaking Down CLB Revenue

Last 7 days

-1.5%

Last 30 days

2.0%

Last 90 days

4.4%

Trailing 12 Months

-22.8%

How does CLB drawdown profile look like?

CLB Financial Health

CLB Investor Care

Dividend Yield

0.27%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	502.8M	0	0	0
2022	477.2M	479.3M	487.3M	489.7M
2021	443.3M	446.3M	458.9M	470.3M
2020	651.4M	598.1M	530.3M	487.3M
2019	692.7M	684.5M	676.4M	668.2M
2018	0	0	0	700.8M
2017	0	0	0	647.8M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Core Laboratories NV

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2023	temeng kwaku	acquired	-	-	5,485	-
Apr 01, 2023	straughen michael	sold (taxes)	-55,654	22.05	-2,524	-
Apr 01, 2023	klingensmith harvey robert	acquired	-	-	5,485	-
Apr 01, 2023	murray katherine	acquired	-	-	5,485	-
Apr 01, 2023	carnes martha z.	acquired	-	-	5,485	-
Apr 01, 2023	van dijken eeuwijk monique	acquired	-	-	5,485	-
Apr 01, 2023	straughen michael	acquired	-	-	5,485	-
Dec 31, 2022	hill christopher scott	sold (taxes)	-252,767	20.27	-12,470	svp & cfo
Dec 31, 2022	hill christopher scott	acquired	-	-	31,688	svp & cfo
Dec 31, 2022	bruno lawrence	sold (taxes)	-727,531	20.27	-35,892	chairman and ceo

Which funds bought or sold CLB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	ARCADIA INVESTMENT MANAGEMENT CORP/MI	sold off	-100	-883	-	-%
Apr 23, 2024	KLR INVESTMENT ADVISORS, LLC	reduced	-6.88	-22,544	191,778	0.14%
Apr 23, 2024	Global Retirement Partners, LLC	sold off	-100	-2,777	-	-%
Apr 23, 2024	FIFTH THIRD BANCORP	added	20.5	1,867	13,152	-%
Apr 23, 2024	WASHINGTON TRUST Co	unchanged	-	-57.00	1,674	-%
Apr 23, 2024	Gradient Investments LLC	unchanged	-	-696	20,496	-%
Apr 23, 2024	Louisiana State Employees Retirement System	reduced	-1.28	-18,696	394,548	0.01%
Apr 23, 2024	AMALGAMATED BANK	reduced	-18.15	-68,000	258,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	-157,188	437,156	-%
Apr 22, 2024	Rosenberg Matthew Hamilton	unchanged	-	-213	6,886	-%

Are Funds Buying or Selling CLB?

Are funds buying CLB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CLB

No. of Funds

Unveiling Core Laboratories NV's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jun 12, 2023	alger associates inc	0%	0	SC 13G/A
Feb 14, 2023	alger associates inc	8.3%	3,853,977	SC 13G/A
Feb 14, 2023	earnest partners llc	7.7%	3,573,101	SC 13G/A
Feb 14, 2023	ariel investments, llc	20.9%	9,703,122	SC 13G/A
Feb 09, 2023	vanguard group inc	11.35%	5,262,192	SC 13G/A
Jan 26, 2023	blackrock inc.	12.6%	5,848,677	SC 13G/A
Jan 20, 2023	blackrock inc.	12.6%	5,848,677	SC 13G/A
Feb 14, 2022	ariel investments, llc	16.9%	7,804,307	SC 13G/A
Feb 11, 2022	earnest partners llc	7.4%	3,433,430	SC 13G/A
Feb 09, 2022	vanguard group inc	10.73%	4,967,126	SC 13G/A

Peers (Alternatives to Core Laboratories NV)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
SLB	70.1B	33.1B	-8.22%	-1.33%	16.68	2.12	17.96%	22.15%
HAL	34.5B	23.0B	0.49%	11.92%	13.04	1.5	13.41%	67.65%
MID-CAP
FTI	11.1B	7.8B	2.14%	89.71%	198.02	1.42	16.77%	152.43%
NOV	7.4B	8.6B	-1.36%	0.27%	7.47	0.86	18.60%	536.86%
CHX	6.6B	3.8B	2.03%	27.36%	21.06	1.76	-1.25%	100.96%
LBRT	3.8B	4.6B	11.37%	65.08%	7.96	0.83	-1.29%	-16.22%
AROC	3.1B	990.3M	3.05%	98.80%	29.52	3.13	17.12%	137.04%
SMALL-CAP
DNOW	1.6B	2.3B	1.54%	38.23%	6.33	0.67	8.66%	93.36%
CLB	681.3M	-	2.04%	-22.82%	28.73	1.36	-	-
DRQ	656.6M	424.1M	-21.00%	-31.42%	1.1K	1.55	17.17%	137.19%
CCLP	344.8M	386.1M	17.68%	82.03%	-36.38	0.89	9.26%	57.09%
BOOM	330.2M	719.2M	-10.48%	-18.86%	12.58	0.46	9.95%	114.41%

Core Laboratories NV News

Latest updates

Core Laboratories NV Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2017Q4
Revenue	0.6%	128	128	126	121	115	125	118	119	108	114	105	116	152	157	173	169	169	-	-
EBITDA Margin	8.0%	0.13*	0.12*	0.12*	0.10*	0.11*	0.14*	0.16*	0.18*	0.14*	-	-	-	-	-	-	-	-	-	-
Interest Expenses	11.3%	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	1.00	3.00	5.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00	-
Income Taxes	-89.7%	1.00	6.00	4.00	2.00	-1.20	9.00	3.00	2.00	2.00	7.00	4.00	-0.26	-4.00	7.00	3.00	5.00	-27.61	6.00	-
Earnings Before Taxes	-75.6%	3.00	13.00	12.00	9.00	-3.00	12.00	4.00	10.00	10.00	20.00	7.00	-5.90	-112	17.00	28.00	24.00	13.00	14.00	-
EBT Margin	17.2%	0.07*	0.06*	0.06*	0.04*	0.05*	0.08*	0.10*	0.11*	0.07*	-	-	-	-	-	-	-	-	-	-
Net Income	-64.8%	2.00	7.00	8.00	7.00	-1.89	3.00	1.00	8.00	8.00	14.00	3.00	-5.72	-108	10.00	24.00	27.00	41.00	9.00	-
Net Income Margin	18.7%	0.05*	0.04*	0.03*	0.02*	0.02*	0.04*	0.07*	0.07*	0.04*	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-148.0%	-5.38	11.00	3.00	-2.59	3.00	2.00	9.00	7.00	5.00	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2017Q4
Assets	2.6%	594	578	570	578	585	581	586	598	584	569	591	614	647	775	788	782	792	649	585
Current Assets	7.7%	228	212	195	200	202	189	187	201	186	166	170	191	220	221	-	-	-	231	-
Cash Equivalents	5.6%	16.00	15.00	14.00	16.00	22.00	18.00	19.00	34.00	28.00	14.00	15.00	21.00	14.00	11.00	13.00	13.00	13.00	13.00	14.00
Inventory	11.4%	67.00	60.00	55.00	53.00	48.00	45.00	44.00	39.00	39.00	38.00	43.00	42.00	52.00	50.00	-	-	-	46.00	-
Net PPE	-2.6%	102	105	107	109	110	111	113	112	113	115	117	120	123	124	-	-	-	123	123
Goodwill	0%	99.00	99.00	99.00	99.00	99.00	99.00	99.00	99.00	99.00	99.00	99.00	99.00	99.00	213	-	-	-	219	179
Current Liabilities	-7.3%	96.00	103	87.00	96.00	100	91.00	93.00	91.00	86.00	90.00	172	99.00	108	112	-	-	-	103	-
Long Term Debt	4.7%	180	172	183	187	190	189	188	208	208	259	190	287	302	305	-	-	-	290	-
Shareholder's Equity	6.0%	195	184	179	174	166	161	161	154	146	76.00	72.00	66.00	70.00	182	195	192	187	161	149
Retained Earnings	2.2%	88.00	86.00	80.00	73.00	66.00	68.00	66.00	66.00	58.00	50.00	37.00	35.00	41.00	161	-	-	-	156	-
Additional Paid-In Capital	8.8%	111	102	106	105	107	101	106	98.00	103	41.00	61.00	61.00	61.00	52.00	-	-	-	57.00	-
Accumulated Depreciation	0.1%	315	315	313	310	307	306	305	301	-	294	-	-	-	-	-	-	-	-	-
Shares Outstanding	0.0%	47.00	47.00	46.00	46.00	46.00	46.00	46.00	46.00	45.00	44.00	44.00	44.00	-	-	-	-	-	-	-
Minority Interest	1.5%	5.00	5.00	5.00	5.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	-	-	-	4.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2017Q4
Cashflow From Operations	-124.0%	-3,169	13,211	5,850	605	5,290	7,154	11,952	9,486	7,987	-11,846	20,693	26,996	22,025	21,302	25,989	17,080	25,156	-	-
Share Based Compensation	2855.3%	8,984	304	2,234	-1,009	6,227	2,447	8,560	3,681	4,405	-8,860	2,859	2,865	10,530	13,700	3,311	7,141	7,200	9,900	-
Cashflow From Investing	-292.6%	-2,038	1,058	-2,557	-2,785	428	-3,694	-3,151	-2,308	-1,070	17,381	-2,374	-3,272	-3,884	-5,134	-7,597	12,259	-5,205	-	-
Cashflow From Financing	148.2%	6,064	-12,573	-5,709	-3,709	-1,384	-4,807	-23,368	-1,367	7,083	-6,875	-24,131	-16,656	-15,343	-18,204	-17,810	-29,999	-19,861	-	-
Dividend Payments	0.4%	466	464	463	463	463	462	463	463	446	445	445	445	11,111	24,406	24,399	24,395	24,374	-	-
Buy Backs	-99.9%	1.00	1,615	145	200	1,920	4,345	2,880	860	171	1,200	157	198	1,238	1,806	411	604	487	-	-

CLB Income Statement

2023-03-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
REVENUES:
Revenue	$ 128,356	$ 115,300
OPERATING EXPENSES:
General and administrative expense, exclusive of depreciation expense shown below	16,331	12,545
Depreciation	3,939	4,384
Amortization	105	173
Other (income) expense, net	(28)	1,637
OPERATING INCOME (LOSS)	6,481	(391)
Interest expense	3,429	2,644
Income (loss) before income taxes	3,052	(3,035)
Income tax expense (benefit)	610	(1,196)
Net income (loss)	2,442	(1,839)
Net income (loss) attributable to non-controlling interest	69	49
Net income (loss) attributable to Core Laboratories N.V.	$ 2,373	$ (1,888)
EARNINGS (LOSS) PER SHARE INFORMATION:
Basic earnings (loss) per share	$ 0.05	$ (0.04)
Basic earnings (loss) per share attributable to Core Laboratories N.V.	0.05	(0.04)
Diluted earnings (loss) per share	0.05	(0.04)
Diluted earnings (loss) per share attributable to Core Laboratories N.V.	$ 0.05	$ (0.04)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic	46,634	46,298
Diluted	47,481	46,298
Service [Member]
REVENUES:
Revenue	$ 91,076	$ 84,723
OPERATING EXPENSES:
Cost of services and product sales exclusive of depreciation expense shown below	70,934	68,857
Product [Member]
REVENUES:
Revenue	37,280	30,577
OPERATING EXPENSES:
Cost of services and product sales exclusive of depreciation expense shown below	$ 30,594	$ 28,095

CLB Balance Sheet

2023-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 16,285	$ 15,428
Accounts receivable, net of allowance for credit losses of $2,436 and $2,214 at 2023 and 2022, respectively	110,699	106,913
Inventories	67,342	60,445
Prepaid expenses	13,197	15,665
Income taxes receivable	13,781	8,190
Other current assets	6,623	5,061
TOTAL CURRENT ASSETS	227,927	211,702
PROPERTY, PLANT AND EQUIPMENT, net of accumulated depreciation of $315,027 and $314,737 at 2023 and 2022, respectively	102,341	105,028
RIGHT OF USE ASSETS	56,663	52,379
INTANGIBLES, net of accumulated amortization and impairment of $17,650 and $17,475 at 2023 and 2022, respectively	7,268	7,483
GOODWILL	99,445	99,445
DEFERRED TAX ASSETS, net	67,025	68,570
OTHER ASSETS	32,948	33,747
TOTAL ASSETS	593,617	578,354
CURRENT LIABILITIES:
Accounts payable	38,366	45,847
Accrued payroll and related costs	23,484	23,431
Taxes other than payroll and income	3,690	4,822
Unearned revenues	5,952	5,942
Operating lease liabilities	11,073	11,699
Income taxes payable	5,133	3,034
Other current liabilities	7,926	8,360
TOTAL CURRENT LIABILITIES	95,624	103,135
LONG-TERM DEBT, net	180,440	172,386
LONG-TERM OPERATING LEASE LIABILITIES	43,793	38,305
DEFERRED COMPENSATION	29,772	31,814
DEFERRED TAX LIABILITIES, net	22,268	22,877
OTHER LONG-TERM LIABILITIES	21,569	20,883
COMMITMENTS AND CONTINGENCIES
EQUITY:
Preference shares, EUR 0.02 par value; 6,000,000 shares authorized, none issued or outstanding	0	0
Common shares, EUR 0.02 par value; 200,000,000 shares authorized, 46,701,102 issued and 46,634,027 outstanding at 2023 and 46,699,102 issued and 46,631,934 outstanding at 2022	1,194	1,194
Additional paid-in capital	111,235	102,254
Retained earnings	87,855	85,949
Accumulated other comprehensive income (loss)	(3,538)	(3,777)
Treasury shares (at cost), 67,075 at 2023 and 67,168 at 2022	(1,360)	(1,362)
Total Core Laboratories N.V. shareholders' equity	195,386	184,258
Non-controlling interest	4,765	4,696
TOTAL EQUITY	200,151	188,954
TOTAL LIABILITIES AND EQUITY	$ 593,617	$ 578,354

About Core Laboratories NV

Core Laboratories Inc. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, reservoir fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and oil delivered products; and proprietary and joint industry studies, as well as services that support carbon capture, utilization and storage, hydrogen storage, geothermal projects, and the evaluation and appraisal of mining activities. The Production Enhancement segment provides services and products relating to reservoir well completions, perforations, stimulations, and production. It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. The company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. The company was founded in 1936 and is based in Houston, Texas.

CEO	Mr. Lawrence V. Bruno
WEBSITE	corelab.com
INDUSTRY	Oil - Services
EMPLOYEES	3600

Core Laboratories NV Frequently Asked Questions

What is the ticker symbol for Core Laboratories NV? What does CLB stand for in stocks?

CLB is the stock ticker symbol of Core Laboratories NV. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Core Laboratories NV (CLB)?

As of Tue Apr 23 2024, market cap of Core Laboratories NV is 681.3 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CLB stock?

You can check CLB's fair value in chart for subscribers.

What is the fair value of CLB stock?

You can check CLB's fair value in chart for subscribers. The fair value of Core Laboratories NV is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Core Laboratories NV is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CLB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Core Laboratories NV a good stock to buy?

The fair value guage provides a quick view whether CLB is over valued or under valued. Whether Core Laboratories NV is cheap or expensive depends on the assumptions which impact Core Laboratories NV's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CLB.

What is Core Laboratories NV's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, CLB's PE ratio (Price to Earnings) is 28.73 and Price to Sales (PS) ratio is 1.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CLB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Core Laboratories NV's stock?

In the past 10 years, Core Laboratories NV has provided -0.204 (multiply by 100 for percentage) rate of return.